Avapritinib (new indication: systemic mastocytosis, ≥ 1 prior therapies)

Subject:

• Active Substance: Avapritinib
• Name: Ayvakyt^®
• Therapeutic area: Systemic mastocytosis
• Pharmaceutical company: Blueprint Medicines (Germany) GmbH

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 15.09.2022

Final decision:

• Hint for a non-quantifiable additional benefit